Research and Markets: Physician and Payer Attitudes Toward Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/63qcfz/physician_and) has announced the addition of Decision Resources, Inc's new report "Physician and Payer Attitudes Toward Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market" to their offering.

“Physician and Payer Attitudes Toward Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market”

"Beginning with the 2010 U.S. launch of Novartis/Mitsubishi Tanabe Pharma's Gilenya (fingolimod), the treatment of multiple sclerosis (MS) has begun a dramatic transformation; over the next decade, we forecast the number of approved agents to double as a diverse array of novel oral and parenteral disease-modifying therapies (DMTs) reach the U.S. MS market, which totaled approximately $6 billion in sales in 2010.

The launch of emerging products, designed to overcome shortcomings in efficacy and/or delivery among current mainstays of treatment (e.g., Copaxone [Teva's glatiramer acetate], Avonex [Biogen Idec's intramuscular interferon-beta-1a]), will bring an expanded variety of treatment options to a field striving for individualized medicine, thereby fulfilling some of the abundant unmet need for treatment alternatives in this market. However, treatment and reimbursement decisions are expected to be become increasingly complex as neurologists and payers grapple with an influx of premium-priced agents that offer a unique balance of benefits, drawbacks, risks, and rewards.

Decision Resources' U.S. Physician & Payer Forum report ""Physician and Payer Attitudes Toward Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market"" explores the current and future landscape for DMT prescribing and reimbursement in MS. We surveyed 100 U.S. neurologists and 20 managed care organization (MCO) pharmacy directors (PDs) to assess their attitudes, expectations, receptivity, and reservations regarding currently marketed and late-stage emerging DMTs for the treatment of MS."

For more information visit http://www.researchandmarkets.com/research/63qcfz/physician_and

Source: Decision Resources, Inc